GLP-1 Coverage Under the Inflation Reduction Act: What Changed

The Inflation Reduction Act (IRA) of 2022 made the most significant changes to Medicare drug pricing in two decades — but it did not automatically make GLP-1 medications like Ozempic or Wegovy free or broadly covered. What it did do is cap out-of-pocket costs for Medicare enrollees, enable drug price negotiation, and create pathways that could affect GLP-1 pricing over time.

What Did the Inflation Reduction Act Actually Change?

Signed into law on August 16, 2022, the IRA introduced several major drug pricing reforms that affect Medicare Part D — the part of Medicare that covers most prescription drugs, including GLP-1 medications. The three biggest changes relevant to GLP-1 users are:

• A $2,000 annual out-of-pocket cap on Part D drugs, phased in starting January 1, 2025.
• Medicare drug price negotiation, allowing the federal government to directly negotiate prices on a select list of high-cost drugs for the first time.
• Insulin cost cap of $35/month for Medicare enrollees, effective January 2023 — important for people using Ozempic for type 2 diabetes who also use insulin.

Additionally, the law eliminated the Part D "coverage gap" (often called the donut hole) starting in 2025, which had previously caused sudden out-of-pocket cost spikes for beneficiaries.

How Does Medicare Price Negotiation Affect GLP-1 Drugs?

The IRA gave CMS the authority to negotiate drug prices directly with manufacturers. The first round of 10 negotiated drugs was announced in August 2023, with negotiated prices taking effect in 2026. GLP-1 medications were not included in that first list.

However, CMS announced a second round of negotiations in 2024, targeting 15 additional drugs for prices effective in 2027. As of the publication of this article, semaglutide-based medications (Ozempic, Wegovy) and tirzepatide-based medications (Mounjaro, Zepbound) had not been selected, but they remain candidates for future rounds as their Medicare spending grows.

The selection criteria under the IRA prioritizes drugs with high Medicare spending and no generic or biosimilar competition — a description that fits GLP-1 receptor agonists closely. Analysts at KFF have noted that GLP-1 drugs could appear on negotiation lists as early as the third or fourth round, potentially affecting prices in 2028 or later.

Does Medicare Currently Cover GLP-1 Medications for Weight Loss?

This is one of the most misunderstood areas. Here is the current breakdown:

• Ozempic (semaglutide 0.5–2 mg) and Mounjaro (tirzepatide): Approved for type 2 diabetes. Medicare Part D plans may cover these when prescribed for that indication, though formulary coverage varies by plan.
• Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide): Approved for chronic weight management. Until recently, Medicare was prohibited by a 2003 law from covering drugs used solely for weight loss. That restriction has not been lifted by the IRA.

In March 2024, the SELECT trial — published in The New England Journal of Medicine — showed that Wegovy reduced major cardiovascular events by 20% in people with obesity and established cardiovascular disease. Following that evidence, CMS issued guidance in 2024 clarifying that Medicare Part D plans may cover Wegovy for enrollees with obesity and cardiovascular disease as a cardiovascular risk-reduction treatment, not solely as a weight-loss drug. This is a significant but narrow expansion.

Timeline: Key IRA Changes and GLP-1 Coverage Milestones

What Does This Mean for People Without Medicare?

The IRA's drug pricing provisions apply specifically to Medicare. If you have private insurance, Medicaid, or no insurance, these changes do not directly lower your GLP-1 costs. However, there are indirect effects to be aware of:

• Negotiated Medicare prices could eventually put competitive pressure on list prices, though this is not guaranteed.
• Manufacturer savings programs like Novo Nordisk's Wegovy Savings Card and Eli Lilly's Zepbound Savings Card remain the primary cost-reduction tool for commercially insured patients, often bringing monthly costs to $25–$150 for eligible patients.
• Medicaid coverage of GLP-1s varies widely by state. The IRA did not mandate Medicaid coverage of weight-loss drugs.

For a detailed look at how manufacturer savings programs work alongside insurance coverage, see our related article on navigating GLP-1 insurance coverage.

Frequently Asked Questions